<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147638</url>
  </required_header>
  <id_info>
    <org_study_id>943871-5</org_study_id>
    <nct_id>NCT03147638</nct_id>
  </id_info>
  <brief_title>Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)</brief_title>
  <acronym>HIT</acronym>
  <official_title>Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshall University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marshall University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For
      Heparin-Induced Thrombocytopenia (HIT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm with retrospective arm The retrospective arm is he comparator and they are historic control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause hospitalization</measure>
    <time_frame>Within six months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>side effects of Warfarin treatment</measure>
    <time_frame>Within six months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Within six months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Heparin-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>1 month</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient treated with Anti coagulation for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard of care , treatment for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin, NOAC</intervention_name>
    <description>duration of treatment</description>
    <arm_group_label>1 month</arm_group_label>
    <arm_group_label>3 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient must be able to provide an informed consent

          -  Patient older than 18 years' old

          -  Patient with suspected diagnosis of HIT, need 2 of the following:

        have a fall in platelet count of &gt; 30% from a baseline prior to heparin/LMWH Platelet
        factor 4 (PF4) ELISA positive Develop skin lesions secondary to subcutaneous heparin With T
        score more than 4 For those less than 4 we will use serotonin release assay-SRA

          -  Patient received the bridging therapy of non-heparin anticoagulant

          -  Patient is receiving the standard of care treatment for HIT

          -  Patient is willing to be followed up for by one of the physicians listed in the
             delegation log

          -  The Primary physician responsible for the patient is agreeing for the patient to
             participate

          -  Patients are not involved in a clinical trial for HIT management

        Exclusion Criteria:

          -  Patient is unable to sign an informed consent

          -  Patient doesn't have a confirmed diagnosis of HIT

          -  Patient Does not have Pulmonary embolus

          -  Patient does is not on Warfarin for other indications

          -  Patient is a known case of hypercoagulable disorder

          -  Patient is not willing to come back for follow up

          -  Patient is critically ill or has a life expectancy of less than 3 months

          -  Pregnancy that is in First trimester.

          -  Multi-system organ failure or estimated survival of less than 30 days

          -  Uncontrolled hypertension defined as a blood pressure &gt;180/110 mm Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>97 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yazan Numan, M.D.</last_name>
    <phone>3045910000</phone>
    <email>numan@marshall.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marshall University</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazan Numan, M.D.</last_name>
      <phone>304-591-0000</phone>
      <email>numan@marshall.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshall University</investigator_affiliation>
    <investigator_full_name>Yazan Numan</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

